Jerome J. Dvonch

CIK: 0001518735

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SNOA

Sonoma Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

SNOA
Sonoma Pharmaceuticals, Inc.
Jul 9, 2026
Award(A)
Restricted Stock Units
Direct
10K shares-
SNOA
Sonoma Pharmaceuticals, Inc.
Jan 2, 2026
Award(A)
Restricted Stock Units
Direct
5K shares-
SNOA
Sonoma Pharmaceuticals, Inc.
Jun 19, 2025
Award(A)
Restricted Stock Units
Direct
13.5K shares-
SNOA
Sonoma Pharmaceuticals, Inc.
Jan 2, 2025
Award(A)
Restricted Stock Units
Direct
10K shares-

		Type	Shares	Price		Ownership
Jul 9, 2026	SNOA Sonoma Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	10,000	-	-	Direct
Jan 2, 2026	SNOA Sonoma Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	5,000	-	-	Direct
Jun 19, 2025	SNOA Sonoma Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	13,500	-	-	Direct
Jan 2, 2025	SNOA Sonoma Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	10,000	-	-	Direct

1-4 of 4 transactions

About DVONCH JEROME J

DVONCH JEROME J (SEC CIK 0001518735) files insider reports with the SEC as Chief Financial Officer of Sonoma Pharmaceuticals, Inc. (SNOA).

Signal8 holds 4 ownership filings by DVONCH JEROME J, all Form 4s, filed between Jan 3, 2025 and Jul 9, 2026. Those filings report 4 transactions, from Jan 2, 2025 to Jul 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on DVONCH JEROME J's filings is in BOULDER, CO.

Recent filings by DVONCH JEROME J

Jul 9, 2026: Grant or award of SNOA derivative securities (Form 4, code A).
Jan 2, 2026: Grant or award of SNOA derivative securities (Form 4, code A).
Jun 19, 2025: Grant or award of SNOA derivative securities (Form 4, code A).
Jan 2, 2025: Grant or award of SNOA derivative securities (Form 4, code A).

Other insiders filing for Sonoma Pharmaceuticals, Inc. (SNOA)

Weigerstorfer Philippe, Director
Trombly Amy Moss, Chief Executive Officer
MCLAUGHLIN JOHN, Director
Jacoby Vanessa, Director
Dal Poggetto John, Controller
Birnbaum Jay E, Director

How to read Form 4 transaction codes